Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage-Reference-Cited by-同舟云学术

Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage

Published:2011-07-17 Issue:11 Volume:25 Page:1437-1439
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Calcagno Andrea,Bonora Stefano,Simiele Marco,Rostagno Roberto,Tettoni Maria C.,Bonasso Marino,Romito Alessandra,Imperiale Daniele,D’Avolio Antonio,Di Perri Giovanni

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference6 articles.

1. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.;Canestri;Clin Infect Dis,2010

2. Blood-brain barrier tight junction disruption in human immunodeficiency virus-1 enecephalitis.;Dallasta;Am J Pathol,1999

3. Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients.;Abdulle;HIV Medicine,2005

4. Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema.;Marchi;Epilepsia,2009

5. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.;Yilmaz;PLoS One,2009

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Metabolism and Transport Capacity of Endothelial Cells, Pericytes, and Astrocytes: Implications for CNS Drug Disposition;2024-08-05

2. Deep analysis of CD4 T cells in the rhesus CNS during SIV infection;PLOS Pathogens;2023-12-07

3. CD4 T cell Responses in the CNS during SIV infection;2023-08-25

4. Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies;Pharmacological Reports;2023-08-21

5. Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs;Expert Opinion on Drug Metabolism & Toxicology;2022-08-03